Steven Pearson, ICER president (Jeff Rumans)
December 21, 2022 08:43 AM ESTUpdated December 29, 09:57 AM
Pharma

TG's MS hope­ful ubli­tux­imab not cost-ef­fec­tive at Ocre­vus' price, ICER says in ev­i­dence re­port

Paul Schloesser

Associate Editor

ICER on Wednes­day re­it­er­at­ed that TG Ther­a­peu­tics’ ubli­tux­imab, a po­ten­tial new ther­a­py for mul­ti­ple scle­ro­sis is not cost ef­fec­tive at the price of $55,081 per …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times